AU2012333092B2 - Synergistic combinations of PI3K- and MEK-inhibitors - Google Patents

Synergistic combinations of PI3K- and MEK-inhibitors Download PDF

Info

Publication number
AU2012333092B2
AU2012333092B2 AU2012333092A AU2012333092A AU2012333092B2 AU 2012333092 B2 AU2012333092 B2 AU 2012333092B2 AU 2012333092 A AU2012333092 A AU 2012333092A AU 2012333092 A AU2012333092 A AU 2012333092A AU 2012333092 B2 AU2012333092 B2 AU 2012333092B2
Authority
AU
Australia
Prior art keywords
combination
mutation
compound
amide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012333092A
Other languages
English (en)
Other versions
AU2012333092A1 (en
Inventor
Markus Boehm
Jan GCE COSAERT
Emmanuelle DI TOMASO
Christine Fritsch
Xizhong Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2012333092A1 publication Critical patent/AU2012333092A1/en
Application granted granted Critical
Publication of AU2012333092B2 publication Critical patent/AU2012333092B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012333092A 2011-08-31 2012-08-30 Synergistic combinations of PI3K- and MEK-inhibitors Ceased AU2012333092B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161529380P 2011-08-31 2011-08-31
US61/529,380 2011-08-31
US201161542463P 2011-10-03 2011-10-03
US61/542,463 2011-10-03
PCT/US2012/052955 WO2013066483A1 (en) 2011-08-31 2012-08-30 Synergistic combinations of pi3k- and mek-inhibitors

Publications (2)

Publication Number Publication Date
AU2012333092A1 AU2012333092A1 (en) 2014-03-06
AU2012333092B2 true AU2012333092B2 (en) 2016-04-21

Family

ID=47720713

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012333092A Ceased AU2012333092B2 (en) 2011-08-31 2012-08-30 Synergistic combinations of PI3K- and MEK-inhibitors

Country Status (11)

Country Link
US (1) US9675595B2 (enExample)
EP (1) EP2750675A1 (enExample)
JP (1) JP6058009B2 (enExample)
KR (1) KR20140072028A (enExample)
CN (1) CN103764144B (enExample)
AU (1) AU2012333092B2 (enExample)
BR (1) BR112014004587A2 (enExample)
CA (1) CA2846454A1 (enExample)
MX (1) MX2014002471A (enExample)
RU (1) RU2607944C2 (enExample)
WO (1) WO2013066483A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
DK2663309T3 (en) 2011-01-10 2017-06-19 Infinity Pharmaceuticals Inc METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
RU2015156221A (ru) * 2013-06-11 2017-07-17 Новартис Аг Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
WO2014203152A1 (en) * 2013-06-18 2014-12-24 Novartis Ag Pharmaceutical combinations
RU2016133285A (ru) * 2014-01-15 2018-02-20 Новартис Аг Фармацевтические комбинации
WO2015160986A2 (en) * 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
JP6724136B2 (ja) * 2015-11-03 2020-07-15 ジェネンテック， インコーポレイテッド がん治療のためのＢｃｌ−２阻害剤及びＭＥＫ阻害剤の組み合わせ
IL263680B2 (en) 2016-06-24 2025-10-01 Infinity Pharmaceuticals Inc PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
EP3849545A1 (en) * 2018-09-10 2021-07-21 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of neurofibromatosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077914A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2007044084A2 (en) * 2005-05-18 2007-04-19 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
RU2192861C1 (ru) 2001-06-29 2002-11-20 Новосибирский институт биоорганической химии СО РАН Композиция для антибластической терапии
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
PL1761528T3 (pl) 2004-06-11 2008-05-30 Japan Tobacco Inc Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
HRP20110621T2 (hr) 2006-09-15 2013-12-06 Pfizer Products Inc. SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
JP2011527703A (ja) 2008-07-11 2011-11-04 ノバルティス アーゲー （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物
ES2609767T3 (es) * 2009-10-12 2017-04-24 F. Hoffmann-La Roche Ag Combinaciones de un inhibidor de PI3K y un inhibidor de MEK

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077914A1 (en) * 2002-03-13 2003-09-25 Array Biopharma, Inc N3 alkylated benzimidazole derivatives as mek inhibitors
WO2007044084A2 (en) * 2005-05-18 2007-04-19 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
BR112014004587A2 (pt) 2017-03-14
CA2846454A1 (en) 2013-05-10
JP2014525454A (ja) 2014-09-29
MX2014002471A (es) 2014-03-27
US9675595B2 (en) 2017-06-13
CN103764144A (zh) 2014-04-30
RU2607944C2 (ru) 2017-01-11
AU2012333092A1 (en) 2014-03-06
RU2014112198A (ru) 2015-10-10
WO2013066483A1 (en) 2013-05-10
CN103764144B (zh) 2016-07-20
EP2750675A1 (en) 2014-07-09
KR20140072028A (ko) 2014-06-12
US20140179744A1 (en) 2014-06-26
JP6058009B2 (ja) 2017-01-11

Similar Documents

Publication Publication Date Title
AU2012333092B2 (en) Synergistic combinations of PI3K- and MEK-inhibitors
AU2019226212B2 (en) Combination of Pl3K inhibitor and c-Met inhibitor
US20160129003A1 (en) Pharmaceutical Combinations
EP2925366B1 (en) Pharmaceutical combinations
KR20180073674A (ko) 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired